Aviko Radiopharmaceuticals is a privately held biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT) to treat a wide variety of cancers. Aviko’s innovative compounds are designed to improve the efficacy of BNCT by targeting and delivering boron to cancer cells with precision. Together with their partners, Aviko is advancing BNCT as a safe, efficacious and convenient treatment modality for patients. Founded by Deerfield Management, Aviko is based at Cure., a healthcare innovation campus in New York City.
Company Details
- Employees
- 10
- Address
- 345 Park Ave S, New York,ny 10010,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://avikobnct.com
- Keywords
- New York.
- HQ
- New York, NY
- Competitors
- Cerberus Radiopharmaceuticals, Telix Pharmaceuticals Limited, Perspective Therapeutics, Nucleis - Radiopharmaceuticals, Neutron Therapeutics LLC, Nucleus RadioPharma, Deerfield Management, Isologic Innovative Radiopharmaceuticals (Isologic), Molecular Targeted Radiopharmaceuticals Holding GmbH, Apertura Gene Therapy.
Aviko Radiopharmaceuticals Questions
Aviko Radiopharmaceuticals's website is http://avikobnct.com
Aviko Radiopharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/avikobnct
Aviko Radiopharmaceuticals has
10 employees.
View email and phone details for 10
employees at Aviko Radiopharmaceuticals.
Aviko Radiopharmaceuticals's industry is
Biotechnology Research
Aviko Radiopharmaceuticals's top competitors are
Cerberus Radiopharmaceuticals,
Telix Pharmaceuticals Limited,
Perspective Therapeutics,
Nucleis - Radiopharmaceuticals,
Neutron Therapeutics Llc,
Nucleus Radiopharma,
Deerfield Management,
Isologic Innovative Radiopharmaceuticals (Isologic),
Molecular Targeted Radiopharmaceuticals Holding Gmbh,
Apertura Gene Therapy.
Aviko Radiopharmaceuticals's categories are Biotechnology Research
